Cargando…

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis

BACKGROUND: Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be conf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wenfan, Fu, Manman, Xu, Xingyuan, Shi, Zeyong, Jiang, Jian, Zhao, Lu, Dai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568994/ https://www.ncbi.nlm.nih.gov/pubmed/37841212 http://dx.doi.org/10.1177/20406223231189224

Ejemplares similares

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
por: Man, Johnathan, et al.
Publicado: (2021)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
por: Lan, Bo, et al.
Publicado: (2018)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects
por: Zhang, Wenjing, et al.
Publicado: (2021)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis
por: Zhang, Qian, et al.
Publicado: (2020)

Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis
por: Guo, Wei, et al.
Publicado: (2017)

Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis
por: Geng, Zhe, et al.
Publicado: (2018)

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022)

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
por: Jin, Liu, et al.
Publicado: (2020)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Polintan, Edgar Theodore, et al.
Publicado: (2022)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis
por: Chen, Yifei, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of Twist overexpression in NSCLC
por: Li, Meng, et al.
Publicado: (2018)

Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis
por: Zhang, Zhen, et al.
Publicado: (2019)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
por: Wu, Bing, et al.
Publicado: (2023)

Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
por: Shen, Jiping, et al.
Publicado: (2022)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis
por: Cheng, Ji, et al.
Publicado: (2019)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
por: Zhang, Xia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_irjfaq9m1q0t4rblsvd2ue9p49